Speedrunning | Shitposttc

By now we’ve all see The Community Update:
But lets talk about reward comparisons:
Note: The Gerbil beat me to the punch this morning on raw math, so for posterities sake
I don’t do things to waste my own time though, so I must have something to add to the conversation!
Things we’re assuming

• CG holds to their word that a daily player will find it fairly easy to hit the top of the F2P track and earn 41,000 currency.
• Although I don’t expect the store to be exactly the same every episode, at least the GC related important stuff will be available in each episode.
• CG doesn’t walk back any of these changes
• Episode 1 Reward Track available: Here

Comparison

Item Name	GC Reward [4red + 4 gold]	Free Track Rewards	Deficit
Kyrotech Salvage	40	24	-16
Omicrons	16	4	-12
Purple Gear Box	32	32	0
Yellow Gear Box	16	16	0
Omega	8	0	-8
Blue Mod	8	0	-8
Purple Mod	8	0	-8
Gold Mod	8	0	-8
Character Shards	200	0	-200
MK1 Amplifier	48	48	0
MK1 Capacitor	160	160	0
MK2 Pulse Mod	80	80	0
MK2 Circuit	140	160	+20
MK2 Thermal	208	256	+48
MK2 Resistor	88	120	+32
Mk2 Micro-Processor	36	48	+12
Injector Salvage	20	60	+40

Lets Go Shopping:
Note: Our goal here first and foremost is to make up the deficit of the Galactic Challenges while using our 41,000 EC. This is not intended to show the most optimal route through the Episode Store, as we’re looking at a specific reward comparison. Number in parenthesis represents “currency left”
Omicrons – 3 available per week @ 800EC/unit
4 weeks * 3 = 12 Omicrons
Total Cost: 9,600EC [31,400EC]
Kyrotech – 2/2 available per week @ 175EC/unit
4 weeks * 2/2 = 8/8 Kyrotech
Total Cost: 2,800EC [28,600EC]
Omega – 5 available per week @ 600EC/unit
We only need to make up 8 [2 weeks] = 8 Omega
Total Cost: 4,800 EC [23,800EC]
Blue Mod – 2 available per week @ 75EC/unit
4 weeks * 2 = 8 Blue Mods
Total Cost: 600EC [23,000EC]
Purple Mod – 2 available per week @ 200EC/unit
4 weeks * 2 = 8 Purple Mods
Total Cost: 1,600EC [21,400EC]
Gold Mod – 2 available per week @ 400EC/unit
4 weeks * 2 = 8 Gold Mods
Total Cost: 3,200EC [18,200EC]
Character Shards

• Available for prices between 1,500 – 2,500EC in quantities of 20
  • Total Cost of 15,000 – 25,000 EC [depending on need]

What about Weeks versus 28 day cycles?
Dex is an asshole and brought this up to me on Discord, so lets play with it:

• There are 52.1 weeks in the year, meaning that in old system you’d receive 208 omicrons in a calendar year
  • There are 13 episodes in a year [364 days] granting 4 omicrons, for a total of 52 omicrons
  • There are 52 Tuesdays in 2025, granting 3 omicrons, for a total of 156 omicrons
  • Total Omicrons in a year 208

Thoughts:

• Overall players will be able to make up their GC deficit and still maintain approximately 18,200EC before accounting for shards
• If end game players don’t buy shards they’ll be trading shard shop currency for the flexibility to buy relic material.
• Non end game players will have the flexibility to decide whether character shards are important to them or not.
• You’re getting more mod slicing material and injector handles either way.
• Overall assuming there is no walk back on the ease of doing episodes this seems like a better system for all people involved

Come join us on Discord: Here

Greetings and Welcome Here.
So the last post brought up a prior discussion Dr. Lalezari had with some college students regarding CD10 mostly and some of CD12. Those were the (2) COVID-19 trials CytoDyn did. There is a stark difference between what Dr. Lalezari was convinced to believe and what the end results became. Dr. Lalezari was there first hand and he appreciated what took place first hand and so he formed his belief system around the actual results.
The interview took place in October of 2020, so, it is over 4 years old and since then, despite what has been said or written in the past 4 years, Dr. Lalezari has not changed his mind or regretted anything he has said in regards to how well leronlimab treats COVID-19, because he knows assuredly, that this disease is a RANTES disease.
I brought this up again, this 4 year old video, I re-hashed it primarily because of the recent paper that was released on the CD10 trial referenced here. It is only in partial form and some snippets are provided, but it suffices to contribute to the fact that COVID-19 is a RANTES disease. This information must be precedented to know the facts and not the lies which have been more widely disseminated. It is provided to reinforce the need to stick with the truth being released now in peer-reviewed published manuscript articles.
Lalezari was present on the front lines of executing CD10 himself. He was a Trooper fighting the war against the disease. With CD10, he saw the actual signal that leronlimab was in fact functioning and executing in COVID-19. These are his words:

“… so I am stunned to see that even in patients with Mild to Moderate illness, leronlimab seems to be having a very significant impact and clear signal of activity and that is the Primary Endpoint now.”

Why did he have that signal?

“… So we found that patients who had a score of at least 4 on day one, meaning they weren’t folks with no symptoms. We had no real effect on patients with no symptoms. Those people tend to get better on their own. But patients who had a score of 4 or more, we reduce symptoms at day 3, from 90% to 70% which is moving the needle…”

Remember, the patients in this trial were only Mild to Moderate. They did not have development of large amounts of CCR5, but despite this, leronlimab still had an impact in the prevention of more severe disease. I stated in the linked post:

“Leronlimab is disease agnostic, variant agnostic and leads to improved healing, better health and longevity and even protects against inflammatory diseases including cancer, arthritis, Alzheimer’s and many others.
Leronlimab is agnostic to pathology. It is not specific to any, rather applicable across the broader spectrum of inflammatory disease.”

How was this recognized? The signal that Dr. Lalezari recognized was NEWS2.

“JL 31:11: Specifically, there’s a thing called a NEWS2 score which is a National Early Warning System score developed by the Royal College of London in England and it’s a score that predicts pulmonary collapse. So, who’s going to end up being intubated in the ICU and it includes things like Respiratory Rate, oxygen saturation, blood pressure, level of consciousness and so on. Seven metrics and this NEWS2 is becoming a very critical End Point in a variety for multiple sponsors. Because, what we really I mean yes, we want to lower muscle aches, but what we really want to do is prevent people from ending up in the ICU intubated and dying. So this NEWS2 predicts who’s going to get into trouble. So if you look at the NEWS2 score on leronlimab versus placebo, we had a statistically significant result at day 3 and at day 14.”

So, Lalezari knew that leronlimab could treat COVID 19 from the NEWS2 signal. Unfortunately, within months of this interview, his zeal for this discovery was not well received.

“With the conclusion of both the CD10 and CD12 clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19. In the smaller study that CytoDyn conducted in patients with mild-to-moderate COVID-19 disease (CD10), there was no observed effect of the drug on the study’s primary endpoint or on any of the secondary endpoints. The primary endpoint for the CD10 trial relied on a measure of participants’ COVID-19 symptoms called a “total clinical symptom score”, which was assigned based on the severity of each participant’s fever, muscle aches, shortness of breath, and cough. This score ranged from 0 (no symptoms) to 12 (all 4 symptoms present and severe). The CD10 trial results showed no clinically meaningful differences in average change in “total clinical symptom score” from baseline to Day 14 between study arms (-3.5 in the leronlimab group versus -3.4 in the placebo group). Additionally, none of the secondary endpoints were met in this study, including mortality, time to symptom resolution, and time to return to normal activity. Taken together, the CD10 results indicate that most study participants experienced resolution in COVID-19 symptoms regardless of whether they received leronlimab or placebo.“

So with respect to CD10, this statement by the FDA is true, but it fails to bring up NEWS2 because the discovery of NEWS2 was post hoc as stated in the recently published paper. Dr. Lalezari acknowledged that CD10 did not meet Primary Endpoint. He told that in this interview to the college students. He also told them about NEWS2, which the FDA completely neglected during this dire time when millions of Americans and tens of millions world wide met their early death due to this disease.

“Findings
Overall, 84 participants were randomized and treated with leronlimab (n = 56) or placebo (n = 28). No difference was observed in change in total symptom score (P = 0.8184) or other pre-specified secondary endpoints between treatments. However, in a post hoc analysis, 50.0% of participants treated with leronlimab demonstrated improvements from baseline in National Early Warning Score 2 (NEWS2) at day 14, compared with 20·8% of participants in the placebo group (post hoc; p = 0.0223). Among participants in this trial with mild-to-moderate COVID-19 adverse events rates were numerically but not statistically significantly lower in leronlimab participants (33.9%) compared with placebo participants (50.0%).”

“… We conclude from CD10 that there’s no question but that there is a signal that leronlimab is working in Covid 19. It’s no longer a question of is it working. It is. Now the question is how well is it working. We are unable to answer that question based on the results from a mild to moderate population because those folks just aren’t sick enough for us to really put the drug to the test.
JL 35:10: The test will be CD12 where patients are in trouble …
… yeah, so what we know is leronlimab works in Covid 19 and it is utterly amazing that we’re doing this interview today because I can make that statement and I know it’s true and I know it’s true for two days now and the world doesn’t realize it yet. We have to break through a lot of media fog but it is true and in as we see CD12, we’ll get again know whether it’s a single, double, triple or home run and then there are questions of well where are we going to use it.”

We all know the story of CD12. His zeal was justified if you consider now the findings of the recently published paper on this topic.
Introduction of the newly released manuscript was made in The 5/30/2024 Webcast:

“In addition to that. now published data, we have two manuscripts from our studies of patients with triple negative breast cancer, a manuscript from our study of HIV positive patients with multi-drug resistant virus, and a manuscript from our study of patients with mild to moderate COVID-19 that have all been submitted from publication and are currently undergoing peer review. In addition, a manuscript detailing results from both our pre-clinical and clinical studies of leronlimab in MASH is undergoing final internal review and will be submitted shortly.”

Excerpts coming from the Published Article “A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19” follow:

The TEMPEST trial was a randomized, double-blind, placebo-controlled study in participants with mild-to-moderate COVID-19. Participants were randomly assigned in a 2:1 ratio to receive subcutaneous leronlimab (700 mg) or placebo on days 0 and 7. The primary efficacy endpoint was assessed by change in total symptom score based on fever, myalgia, dyspnea, and cough, at end of treatment (day 14).
However, in a post hoc analysis, 50.0% of participants treated with leronlimab demonstrated improvements from baseline in National Early Warning Score 2 (NEWS2) at day 14, compared with 20·8% of participants in the placebo group (post hoc; p = 0.0223).
However, the results of the exploratory post hoc analysis showing that participants in the leronlimab group had greater improvement in NEWS2 assessment compared to placebo provided a suggestion that leronlimab may be associated with a lower likelihood of people with mild-to-moderate COVID-19 progressing to more severe disease and needs to be confirmed in other appropriately designed clinical trials.
CD10 Clinical Trial Results
Moreover, people with the CCR5-Δ32 gene variant, which decreases cell surface expression of CCR5 and attenuates pro-inflammatory responses, were shown to have a significantly reduced risk of severe COVID-19.
Collectively, these findings provide compelling evidence that hyperactivation of CCR5 contributes to the pathological inflammatory response seen in severe and critical disease and highlight CCR5 as a potential therapeutic target in COVID-19.
Recently, several case studies of people with severe or critical COVID-19 demonstrated that leronlimab treatment was associated with a reduction in elevated plasma IL-6 and CCL5, normalized CD4/CD8 ratios, and was associated with high rates of recovery, suggesting clinical benefit.

These excerpts prove that what Dr. Lalezari was saying 4 years prior to the peer-reviewed publication was spot on. Now, the published manuscript says so. He knew it all along, as did all the long shareholders. The peer-reviewed published manuscript validates that leronlimab could have effectively provided clinical benefit even to patients with mild to moderate COVID-19, (mild to moderate levels of CCR5). Essentially saying that leronlimab could be used as a prophylactic medication in COVID-19, to ward off more severe disease. Will that be pursued? Will another corona virus come to destroy the world?
So where is CytoDyn going today? November 16, 2024?

“These last five months have been really utterly awful and I know I have PTSD from it and in part it’s awful because we didn’t go into this in detail, but we actually knew leronlimab was working back in March because there were various doctors and families around the country who had called and said they wanted you know emergency access to leronlimab through the right to try program and so the FDA issued individual investigational new drug approvals for about 85 patients who were then treated at various hospitals around the country in New York; in Georgia; in Los Angeles and we were able to collect data on those patients and we knew we CytoDyn knew that the drug was working back in March and certainly in April and we knew it was working before we knew how it was working and we certainly knew it was working before everybody started dying and there wasn’t any way to break through the media, the government, the FDA because nobody believed us because there are a hundred companies out there saying we have the cure to Covid, but we knew we did not necessarily the cure, but we had an effective treatment, because even though these were not randomized patients, normally you have to do a randomized study in order to remove hidden biases, so that your treatment and placebo groups are balanced for things that you know about and things that you don’t know about. Well, we didn’t have a randomized arm control arm, but we were treating the patients who were on death’s door so there wasn’t a lot of, you know, randomization bias. If anything, we were treating the sickest of the sick and a lot of these folks died, but we looked at their lab results and before they died they were able to show us that the drug was working in that we saw reduced levels of the cytokine IL-6. We saw increases in the CD8 counts and balancing of the immune system and so there were a bunch of people who died and the last thing they did before they died was show us at CytoDyn that the drug was working, but nobody would believe that data because it wasn’t really randomized data and nobody acts on data without a control arm.
JL 54:00: So we have had to hustle you know, to get the CD10 study, the CD12 study, first approved by the FDA and then we had to get them enrolled, which was incredibly difficult in an environment where Gilead and other large companies rose, Genentech, were doing their own clinical studies and and just had far more resources than this little company CytoDyn which started as a nickel, 30 cent stock. They just didn’t have the money to throw at this the way a big company would and certainly NIH and our government, nobody has helped CytoDyn with anything. So, it was extremely traumatizing to to look at the results from the emergency IND patients, be pretty sure we had a treatment that was working, even in patients who were really ill, and then to not even know exactly how it was working, which cells it was affecting trafficking, or but then to have to start from scratch, while you know we’re hearing reports like there are not enough ventilators in New York and then to see 150 probably closer to 200 000 people now die and just in the US, while we have been scrambling to get these studies filled, enrolled and then now analyzed, it has been psychologically and spiritually exhausting and there’s really nobody in a position of any authority that has helped us at all and I’m trying not to be bitter about it.
56:00: Okay. Thank you. Do you have any closing remarks for us today?
JL 56:07: I just say thank you. I enjoyed talking with you. I’m sure I ran on more than you anticipated. Certainly more than I anticipated. It’s incredible that you asked to do this interview this day. I know one thing. I’ve learned about Covid is I’ve had to learn to trust the process. There’s a hand in the universe. Mama gaia, she’s got it. Things are happening for a reason sometimes we don’t understand why. I actually want you to know. It means a lot that we did this interview today because these feelings that I’m having this information that I’m sharing is both raw and fresh. You know we’ve submitted to the FDA now and we’re submitting to the regulatory authorities in England, in Mexico, Brazil hopefully Israel and and you are about to hear more about leronlimab in the coming weeks and or month, six weeks, you know CD12, certainly by October first. Hopefully, but no one right now knows about it except you and me and a few other people and CytoDyn’s investors. So, it’s incredible that we’ve had this opportunity and I’m grateful to have had this opportunity to share this with all of you.”

Can you relate to Lalezari? What were his instincts then? His instincts haven’t changed. Maybe he is now more disciplined, but his instincts are the same. So then, Where is this published paper going? England, Mexico, Brazil, Israel. What should CytoDyn Investors be looking for? More of these sorts of peer reviewed published manuscripts, because they go round the world. These papers are the proof of what CytoDyn knows as truth. So let it be known world wide what CytoDyn knows first hand. It gives validity to CytoDyn’s partners that the moves they initiate are well founded and may be banked on to create a medication in combination capable of re-creating the effects of the CCR5 delta 32 mutation. The peer reviewed papers declare leronlimab’s inherent and proven effectiveness and safety. Partnership is fostered.
The papers shall continue to come. The partnership shall also come. Lalezari knew 4 years ago, leronlimab treats COVID-19. The paper today proves it. Let’s stick with what the papers say so we can know what is coming next.

NSN, Aviation Electronic Parts at Opti Aero/Optiaero P49708-334 Preformed Packing Marine Electronics Llc Part of FSC 5330 Packing And Gasket Materials
Request For Quote:https://www.optiaero.com/request-quote/
43B01606PC1136T01141 Part NIIN 006399106 NSN 4820006399106 By Northrop Grumman Systems Corporation
659567 Part NIIN 004119890 NSN 4710004119890 By Kreisler Industrial Corporation
RN60E1153F Part NIIN 000881003 NSN 5905000881003 By Military Specifications
NAS698A6 Part NIIN 007616867 NSN 5310007616867 By National Aerospace Standards
1980M71G01 Mounting Bracket Part of FSC 5340 Hardware, Commercial NIIN 014607470
396-2200-1509511PCF5 Part NIIN 002889875 NSN 4720002889875 By Naval Sea Systems Command
3248643 Part NIIN 002027865 NSN 4720002027865 By Mtu Detroit Diesel Inc.
9439 Part NIIN 004469366 NSN 4820004469366 By Northrop Grumman Systems Corporation
CAV25-5P Part NIIN 008275497 NSN 5310008275497 By Recon/Optical Inc.
580-204-1700462REVAPC29 Part NIIN 005762310 NSN 5325005762310 By Naval Ship Systems Command
NASM3 THRU NASM20-AN5H11A Machine Bolt Part of FSC 5306 Bolts NIIN 001822028
3013939-4-4-4C-15.00-000 Part NIIN 011126219 NSN 4720011126219 By Parker-Hannifin Corporation
934150-111 Part NIIN 001764650 NSN 4720001764650 By Raytheon Company
2UUA0583 Part NIIN 000401497 NSN 4710000401497 By Volvo Trucks North America Inc.
D792324-18 Part NIIN 011852032 NSN 5305011852032 By Huck Intl Inc
Y40112-29 Part NIIN 008841234 NSN 4730008841234 By Smiths Tubular Systems-Laconia Inc.
FFIL-0-303 1/2BN Part NIIN 008269951 NSN 5305008269951 By Honeywell Intl Inc
MS21090-348 Part NIIN 011010715 NSN 5305011010715 By Military Standards
2100-983088ALTBPC3SLEEVE Naval Ship Systems Command Part NIIN 005401705 NSN 4730005401705
RB17CE10202F Part NIIN 000600456 NSN 5905000600456 By Military Specifications
180-356 Knob Part of FSC 5355 Knobs And Pointers NSN 5355005437183
61H828-6 Hexagon Self-Locking Nut Part of FSC 5310 Nuts And Washers NIIN 002752088
TYPEN023-16X1 Groov-Pin Corporation Part NIIN 000442933 NSN 5315000442933
845-4687545 ITEM 6QA Part NIIN 009331604 NSN 4820009331604 By Naval Inventory Control Point
10863350 Gasket U S Army Tank Automotive Command Part of FSC 5330 Packing And Gasket Materials
WA1523 Flat Washer Part of FSC 5310 Nuts And Washers NIIN 004284336
37E501321P101 Part NIIN 007334242 NSN 4710007334242 By General Electric Co
GCP389PC10 Packing Assembly M. T. Davidson Company Part of FSC 5330 Packing And Gasket Materials
HT4049-4-8 Part NIIN 011467292 NSN 5305011467292 By Sps Technologies Llc
1-110-114-08 Part NIIN 008884754 NSN 4730008884754 By Norman Noble Inc.
12428 Part NIIN 007802395 NSN 4820007802395 By Eaton Corporation
1086 Part NIIN 006248146 NSN 5305006248146 By American Telephone And Telegraph Co
100000-1297 Part NIIN 000170228 NSN 5905000170228 By Aeronautical Instrument & Radio Co
J23061404-0122 Part NIIN 011270484 NSN 4720011270484 By Smiths Tubular Systems-Laconia Inc.
6789332 Part NIIN 006756805 NSN 4710006756805 By Rolls-Royce Corporation
ASTM 120 Part NIIN 001621018 NSN 4710001621018 By American Society For Testing And
696-8300-24 Part NIIN 010613177 NSN 4720010613177 By Aqua-Chem Inc.
HR101H4-17 Part NIIN 009289599 NSN 5305009289599 By Hi-Shear Corporation
3611740-0001 Part NIIN 011744533 NSN 5305011744533 By Honeywell International Inc
8613343 Part NIIN 007084046 NSN 5310007084046 By Hydramatic Div
103343 Part NIIN 008108336 NSN 5310008108336 By Mtu Detroit Diesel Inc.
60-FL3/16 Imperial Part NIIN 003394873 NSN 4730003394873
MIL-DTL-1222 Machine Bolt Part of FSC 5306 Bolts NIIN 004044165
NMP181PC19 Part NIIN 006311026 NSN 4820006311026 By Kunkle Industries Inc
11613568 Part NIIN 001778541 NSN 4710001778541 By U S Army Tank Automotive Command
AN23-18 Clevis Bolt Part of FSC 5306 Bolts NIIN 001511970
8679620 Part NIIN 003383519 NSN 4710003383519 By U S Army Tank Automotive Command
13044578 Machine Screw U S Army Aviation And Missile Part of FSC 5305 Screws
9690M55P03 Part NIIN 013716925 NSN 4710013716925 By General Electric Company
JCM-15008 Part NIIN 013198064 NSN 4710013198064 By Strike Weapons And Unmanned Aviation
B270-5 Part NIIN 008252498 NSN 5310008252498 By Circor Instrumentation Technologies
3M123-3-24P Part NIIN 011705560 NSN 5305011705560 By Alcoa Global Fasteners Inc.
1683140 Part NIIN 007827935 NSN 5310007827935 By Navair And Navsea Managed
MA 12600-26 Part NIIN 007287712 NSN 5310007287712 By Sps Technologies Llc
6SA125 Part NIIN 003668174 NSN 4820003668174 By Snydergeneral Corp
T2S632BC Part NIIN 007796911 NSN 5310007796911 By Sps Technologies Llc
8100-0100 Part NIIN 007669819 NSN 5310007669819 By Genrad Inc
1004705-1 Part NIIN 007874556 NSN 5310007874556 By Emerson Power Transmission
93S1 Gasket L L Rowe Company Part of FSC 5330 Packing And Gasket Materials
NAS1189C4P6L Part NIIN 005816484 NSN 5305005816484 By Alcoa Global Fasteners Inc.
12063 Part NIIN 011461655 NSN 5305011461655 By Eaton Corp
4726 Part NIIN 009163596 NSN 4820009163596 By Saylor-Beall Manufacturing Company
UWN1812 Part NIIN 006876566 NSN 5310006876566 By Sps Technologies Llc
802223-13 Part NIIN 011426841 NSN 5305011426841 By Raytheon Company
365242-1 Part NIIN 009847766 NSN 4720009847766 By Stanley Aviation Corp
002885 Kollmorgen Corporation Part NIIN 000868306 NSN 5315000868306
G-2459-114 P/N101826 Part NIIN 011870244 NSN 5305011870244 By Flexi-Mat Corp
MS24692-286P Military Standards Part NIIN 000519896 NSN 5315000519896
151069A Part NIIN 011523365 NSN 4720011523365 By Dresser Industries Inc
908074 Part NIIN 007007557 NSN 5310007007557 By Sasco Inc Canadian Div
P46598 Machine Bolt Part of FSC 5306 Bolts NIIN 001732868
6829343 Part NIIN 000669670 NSN 4710000669670 By Allison Transmission Inc.
888C1055-2 Knob Part of FSC 5355 Knobs And Pointers NSN 5355000546381
564994 Part NIIN 009129842 NSN 4720009129842 By Vme Americas Inc
124F001-16CR-0290 Part NIIN 003379830 NSN 4720003379830 By Parker-Hannifin Corporation
1363HX1 Machine Bolt Part of FSC 5306 Bolts NIIN 000501239
7409500 Part NIIN 011820733 NSN 4710011820733 By U S Army Tank Automotive Command
ADH7762A Part NIIN 010998666 NSN 5305010998666 By Fairbanks Morse Engine
B-AX-1076 Part NIIN 011778427 NSN 5305011778427 By Eaton Aerospace Llc
BACD40A6-74-6A1 Part NIIN 010483500 NSN 4720010483500 By The Boeing Company
PARTC1 Part NIIN 009007523 NSN 4730009007523 By Ever Tite Coupling Co Inc
4-40X3-4 Part NIIN 007225006 NSN 5305007225006 By Proverbs 31 Investments Llc
DAA3122U452 Part NIIN 013522449 NSN 4710013522449 By Vought Aircraft Industries Inc.
GR520G-250 Part NIIN 000369305 NSN 5325000369305 By Northrop Grumman Systems Corporation
13000006-0410F Part NIIN 000186393 NSN 4720000186393 By Smiths Tubular Systems-Laconia Inc.
MIL-F-5509 Military Specifications Part NIIN 004123466 NSN 4730004123466
NAS1112-20D Shear Bolt Part of FSC 5306 Bolts NIIN 001448264
12294540 Part NIIN 011488884 NSN 5305011488884 By U S Army Tank Automotive Command
785-0042-001 Rockwell Collins Inc. Part NIIN 004794673 NSN 4730004794673
6748072-106 Part NIIN 000593118 NSN 5325000593118 By Allison Transmission Inc.
3R2299 Part NIIN 008819425 NSN 5305008819425 By Caterpillar Inc.
S1021Z8-6 Part NIIN 008387439 NSN 5305008387439 By Reed And Prince Mfg Co
SD52196 Part NIIN 006394740 NSN 5305006394740 By Ambac International Corporation
AN515-5-12 Part NIIN 005052605 NSN 5305005052605 By United Technologies Corporation
MIL-R-93/4 Part NIIN 000521680 NSN 5905000521680 By Military Specifications
18H3892D248 Part NIIN 007409885 NSN 5310007409885 By Morris Material Handling Inc.
5124796 Gasket General Motors Corp Part of FSC 5330 Packing And Gasket Materials
NASM585 Part NIIN 005760450 NSN 5305005760450 By National Aerospace Standards
CVC241AC4-9 Machine Screw Vought Aircraft Industries Inc. Part of FSC 5305 Screws
1162A3 Part NIIN 007521956 NSN 5310007521956 By Diamond Reo Truck Co
DD364S61-0409PC13 Naval Ship Systems Command Part NIIN 003642943 NSN 4730003642943
9-193416-01 Knob Part of FSC 5355 Knobs And Pointers NSN 5355010247383
5749809-237 Part NIIN 012277418 NSN 4710012277418 By Textron Inc.
40659 Gasket Mitsubishi Caterpillar Forklift Part of FSC 5330 Packing And Gasket Materials
65307-08056 Part NIIN 013208555 NSN 4710013208555 By Sikorsky Aircraft Corporation
944061 Part NIIN 009333719 NSN 4720009333719 By Am General Llc
SS2100-935083PC5 Part NIIN 005338345 NSN 4820005338345 By Naval Inventory Control Point
MIL-R-93/15 Part NIIN 000612102 NSN 5905000612102 By Military Specifications
91422 Machine Bolt Part of FSC 5306 Bolts NSN 5306006379790
NAS1303-2H Shear Bolt Part of FSC 5306 Bolts NIIN 000688990
RNC65H4640FP Part NIIN 000487138 NSN 5905000487138 By Military Specifications
64A98D420-8 Part NIIN 001321230 NSN 4720001321230 By Naval Air Systems Command
817578 Part NIIN 008919967 NSN 4730008919967 By American Hoist And Derrick Co
11958 Part NIIN 003369245 NSN 4820003369245 By Grove Valve Operations
10293109-3 Part NIIN 003688369 NSN 4710003688369 By U S Army Aviation And Missile
NAS1189-06P6L Part NIIN 009640872 NSN 5305009640872 By Fastener Innovation Technology Inc
547130 Part NIIN 009172565 NSN 4720009172565 By Turbo Power & Marine System Inc
CMF55X018F154R0F Part NIIN 000781547 NSN 5905000781547 By Vishay Dale Electronics Inc.
3290HJ67-503 Part NIIN 000046005 NSN 5905000046005 By Bourns Instruments Inc
400-340 Part NIIN 008333054 NSN 5310008333054 By Jaidinger Mfg. Co. Inc.
SM-B-630704 Knob Part of FSC 5355 Knobs And Pointers NSN 5355010298983
659579 Part NIIN 004122931 NSN 4710004122931 By United Technologies Corporation
1286303-1 Part NIIN 006765534 NSN 5310006765534 By Honeywell Intl Inc
C4BM1748-1 Knob Part of FSC 5355 Knobs And Pointers NSN 5355008203450
49-5112 Step Bolt Part of FSC 5306 Bolts NIIN 000552084
465C77-3 Part NIIN 007800393 NSN 4820007800393 By Auto-Valve Inc.
SC86 Machine Screw Rfi Corporation Part of FSC 5305 Screws
366994PC6 Scale Dial Part of FSC 5355 Knobs And Pointers NSN 5355001573901
7119358 Packing Assembly Army United States Department Of The Part of FSC 5330 Packing And Gasket Materials
13142696 Part NIIN 011193617 NSN 5305011193617 By U S Army Aviation And Missile
TW-3 Shoulder Screw Mjt Holdings Llc Part of FSC 5305 Screws
MS3217-1137 Part NIIN 001748678 NSN 5325001748678 By Military Standards
P2528 Part NIIN 002816692 NSN 5325002816692 By Koehring Co
M Part NIIN 002026716 NSN 4720002026716 By Goodyear Tire And Rubber Co The
1208-1 Part NIIN 003407484 NSN 5325003407484 By Eaton Corp
191046 Part NIIN 006965110 NSN 5305006965110 By U S Army Tank Automotive Command
LL57J40S4 Socket Head Cap Screw Long-Lok Fasteners Corporation Part of FSC 5305 Screws
AH714L Part NIIN 009362971 NSN 5305009362971 By Ametek Inc.
14291 Part NIIN 008922260 NSN 4820008922260 By Mark Controls Corp
51500-59-811PC21 Naval Ship Systems Command Part NIIN 004691783 NSN 4730004691783
MS15795-410 Part NIIN 007270858 NSN 5310007270858 By Military Standards
LK21262-51 Part NIIN 009432063 NSN 5305009432063 By Torkon Fastener Corp
AM82S42-182PC109 Part NIIN 003343849 NSN 4820003343849 By Naval Ship Systems Command
819004-012 Part NIIN 008540466 NSN 5305008540466 By Allied Signal Inc
MIL-F-18240 Part NIIN 009320858 NSN 5305009320858 By Military Specifications
H732170003 Part NIIN 007276528 NSN 5305007276528 By Kearfott Corporation
100965 Hexagon Plain Nut Part of FSC 5310 Nuts And Washers NIIN 003589955
C547-4-0114H Part NIIN 002792708 NSN 4720002792708 By Lockheed Martin Corporation
01Y7096 Part NIIN 001749829 NSN 5325001749829 By Ford Motor Co

I’m working as a compliance analyst at one of the major banks in Belgium. Recently I got an offer from a smaller bank. I’ve put the new offer in bold. What do you think of my current salary package and the offer I’ve received?
1. PERSONALIA

• Age: 31
• Education: master of laws
• Work experience : 6 years
• Civil status: single
• Dependent people/children: 0

2. EMPLOYER PROFILE

• SectoIndustry: banking (pc 310)
• Amount of employees: >5.000
• Multinational?

3. CONTRACT & CONDITIONS

• Current job title: compliance analyst
• Job description: mainly working on anti-money laundering
• Seniority: 2,5 years at current empoyer
• Official hours/week : 37 same
• Average real hours/week incl. overtime: +/- 40
• Shiftwork or 9 to 5 (flexible?): 9-5 (flexible hours)
• On-call duty: no
• Vacation days/year: 41 37

4. SALARY

• Gross salary/month: 4600 4000
• Net salary/month: +/- 2800 (without netto compensation) should be around 2.500 I think
• Netto compensation: 65 150
• Cabike/… or mobility budget: possibility to lease a bike or car (not needed for the moment) car TCO 900 (or mobility budget)
• 13th month (full? partial?): no classic 13th month but a fixed bonus +/- 3.000 net classic 13th month no idea how much (should be around 1.800 euro net)
• Meal vouchers: 8 euro/dag 8 euro/dag
• Ecocheques: 150 euro i believe no
• Group insurance: +/- 340 contribution per month +/- 260 contribution per month (both fully by employer)
• Other insurances: hospitalization insurance, disability insurance (+ possibility of insurances with reduction) hospitalization insurance, disability insurance
• Other benefits (bonuses, stocks options, … ): yearly profit bonus of +/- 2.700 net, performance bonus of +/- 1.100 net, possibility to buy stocks with reduction, benefits@work yearly profit bonus of +/- 3.200 net, collective bonus of +/- 400 net, , benefits@work

5. MOBILITY

• City/region of work: region Brussels region Antwerp
• Distance home-work: 45 minutes single trip way more traffic so should be around 1u-1u15
• How do you commute? public transportation (no car needed at this moment) I will have to opt for the company car a going to the new workplace by public transport would be a pain in the *ss.
• How is the travel home-work compensated: free train pass car or mobilitybudget
• Telework days/week: max 50% 2 days/week

6. OTHER

• How easily can you plan a day off: very easy
• Is your job stressful? sometimes
• Responsible for personnel (reports): no no

The Classical Christian tradition is the tradition of the historic tradition of figures such as the Church Fathers as well as those men and women of faith who were the pillars of what became Christian theology and Christian orthodoxy. One of the things that I want to argue is that many of the Classical Christian approaches to reading and interpreting the Old Testament makes sense from a logical and moral perspective. Now before I go on I just want to make a brief preface. Given that this sub is “Debate religion” the topic of my post does not have a specific group of people it is addressed to. It is addressed to people regardless of whether or not they are Christian, non Christian, theist or atheist. I have to say this because it is noticeable that whenever I make a post on the Old Testament or even a post in general, the most frequent responders tend to be atheists or those who come from a secular perspective. Which creates the false impression that that’s the specific audience I am addressing. That is false. This post is broadly addressed to different people regardless of their religious persuasion. And it is done from a Christian perspective. So here are the reasons and perspectives for the arguments I am giving.
1)Distinguishing between the literal and spiritual reading of scripture

• In the tradition of the Church Fathers there is a distinction that is made between the “literal” and “spiritual” reading of the Biblical text. What this means is that the text cannot be reduced down to only its literal meaning. Now what is the basis for this? If you start from the axiom that scripture is written by human beings but is the inspired word of God then, as the Catechism of the Catholic Church points out, scripture has two sets of authors. The literal reading of the text helps us to uncover the original intention of the human authors. The spiritual reading of the text helps us to uncover the original intention of the Divine author which in Christian theology is the Holy Spirit. And we do so by reading the text in an allegorical, moral and what is called an “anagogical” manner. This means the text cannot be reduced to what the original human authors thought, even though that is important. It’s much more than that.
• The second basis for the allegorical and spiritual reading of scripture is rooted in is scripture itself. St Paul for example when reading the Old Testament text uses the allegory when speaking about the Old and New covenant. In his letter to the Galatians he uses the analogy of Sarah and Hagar as examples of the difference between the different covenants as well as the Law and Gospel. Jesus in the Gospels when speaking of the resurrection of the dead appeals to God’s word in the Exodus story where he states he is the God of “Abraham, Isaac and Jacob”. Jesus states “he is the God of the living not the dead”. That is a straightforward allegorical reading of the text. When we go back to the Hebrew Bible itself we see allegory being used. For example in the law code of Deuteronomy it speaks of the penalties of adultery for an adulterous woman. In the prophetic texts of Ezekiel in Ezekiel 23 the prophet uses the analogy of an adulterous woman that is stoned as an allegory for Israel and its sins and the judgement that it faced as a nation. So the allegorical interpretation has its roots in scripture itself.
• The allegorical reading of the Old Testament is demonstrated in many different instances. When it comes to the war passages such as the Israelite conquest of Canaan in Deuteronomy and Joshua or the Israelite war with Amalek one of the themes present is the concept of “the ban”. This translates in some cases as “utterly destroy” or “destroy all that breathes”. For the Church Fathers the passages that speak about “the ban” symbolize our struggle against sin. So for example in Deuteronomy when it speaks of the 7 nations that must be “utterly destroyed” Fathers such as St John Cassian saw that as a command to do battle against the deadly sins. Sins such as greed, envy, hatred we must conquer and “utterly destroy them”. Similarly in some of the Biblical texts such as Exodus 11, 1 Samuel 15 or Psalm 137 it speaks about destroying the “children” and the “offspring”. Fathers such as St Gregory of Nyssa in his work “the Life of Moses” saw this as also symbolizing the struggle against sin. That we must destroy not only sin itself, but the offspring that sin produces. So greed is a sin. We must destroy not just greed. But we must destroy exploitation, domination and oppression which are the offspring of greed. The allegorical reading doesn’t just apply to the war narratives. It also applies to some of the legal texts as well. For example Exodus 21 speaks about laws surrounding slavery. One set of laws speaks of the indentured servant who works for 6 years and is released on the 7th. The other speaks of the slave who remains attached to their master and chooses to become a permanent slave through a mark. St Ambrose and St Jerome saw this as symbolizing the relationship between individuals and the desires of the world. The indentured servant represents the righteous person who gives up their sins after serving the wickedness of the world and strives for the path of righteousness. The permanent servant represents the wicked person who is so attach to the sin of the world that it becomes his permanent master. When read in this sense they definitely impart a series of moral lessons. Which is why the allegorical and moral reading of scripture are connected under the spiritual approach.
• One objection to this approach is the notion of convenience. “You conveniently allegorize the parts of the Bible you don’t like while not allegorizing the parts you like”. False. The allegorical reading of scripture applies regardless of whether we are talking about the “nice” or “not nice” parts of scripture. The Songs of Solomon for example is a love story that has no violence involved in it. And yet that is also read in an allegorical manner in both the Christian and Jewish traditions respectively as speaking of the relationship between God and his people.
• Another objection would be the question of why God would even feel the need to allow allegories and metaphors in his sacred text in the first place. St Thomas Aquinas in the Summa directly answers this when he states “It is befitting Holy Writ to put forward divine and spiritual truths by means of comparisons with material things. For God provides for everything according to the capacity of its nature. Now it is natural to man to attain to intellectual truths through sensible objects because all our knowledge originates from sense….It is also befitting Holy Writ, which is proposed to all without distinction of persons that spiritual truths be expounded by means of figures taken from corporeal things, in order that thereby even the simple who are unable by themselves to grasp intellectual things may be able to understand it”(Summa Theologica Pt 1, Q 1, Art. 9). Precisely because God is transcendent, and human beings are finite creatures who reason their way in the word through sense and experience, scripture reveals its truths through the metaphors and analogies of human experience. Hence why it is justified to use metaphor and allegory.
• Another issue that people mention is that if you take this passage allegorically, doesn’t that just open the flood gates to interpret the text however you like by your own whims? Aquinas again addresses this topic when he speaks of the relationship between a word, a thing that a word is describing, and what can be signified by that thing. Aquinas talks about “the word” and the thing it is describing as the literal reading of the text. So for example if Plato writes the words “the Republic” the words themselves and city state described by the words is the literal reading. The “Republic” and what it symbolizes in terms of the different states of the soul is the allegorical reading. There has to be a causal connection between word, thing and signification for a reading to have any legitimacy, especially in the context of the Bible. So if I expound an allegorical reading that has no causal connection to the substance of either the words or the thing itself it is not a real signification. If I expound a “literal” reading that also has no causal connection to the words that’s not a legitimate reading of the text. So in that Hermeneutical sense I can’t just “make things up” at my whim.

2)The relationship between the text and the intentions of the reader

• This is a principle that is articulated by St Augustine of Hippo. That the intention that we bring to the text is just as important as our understanding of the text itself, and that is crucial to the Bible and the Old Testament specifically. In his Soliloquies when speaking about God in general he talks about how our minds have to be purified by the virtue and reason in order to have a proper understanding of God. In his work “On Christian Doctrine” when it comes to the Word of God he speaks about how the principle of Love is the foundational intentional key to understanding the text. This is because in the Christian belief system God is Love(1 John 4:8) and the commandments that he gives us, to Love God and love our neighbor is rooted in the principles of Love. Hence why Augustine states “So anyone who thinks that he has understood the scriptures, or any part of them, but cannot by his understanding build up this double love of God and neighbor, has not yet succeeded in understanding them”(On Christian Doctrine) Therefore any interpretation of scripture that goes against the principle of Love, whether it’s love of God or Love of neighbor is a false interpretation. The scripture expounds at length what “love your neighbor means”. In the OT it includes loving the stranger like what is command in Leviticus with the alien as well as what we see in stories like the Book of Ruth. In the New Testament it is demonstrated in the Parable of the Good Samaritan. Any reading of the text that violates the principle of love of neighbor is a false reading of the text. Any text itself that at its surface seems to go against the principle of love of neighbor is not something that can or should be read at a surface level.
• The principle of examination of intentions in interpreting and reading scripture is something that goes back to the text itself. In Psalm 50 for example it explicitly states “But to the wicked God says “What right have you to recite my statutes or take my covenant on you lips?”(Psalm 50:16). Furthermore St Paul speaks of the concept of “soundness of doctrine” and how “the aim of such instruction is love that comes from a pure heart, a good conscience, and a sincere faith”(1 Timothy 1:5). With that in mind any use or weaponization of the Old Testament to justify things such as violence, slavery, oppression, or injustice of any kind under this reading is a false reading of the text due to the intention that is brought to the text in the first place. And that is rooted in the principles of scripture itself.

3)Distinguishing God and our experience of God

• This understanding is really brought to the forefront in the theology of St Gregory Palamas, the great Medieval theologian in the Eastern Christian tradition. He famously made a distinction between God’s essence and God’s energies. God’s essence is just that. The essence of who he is. God’s energies is the manifestation of his grace in the world. Palamas uses the analogy of the Sun and the rays of the sun. Experiencing its rays does not mean that that you are in the middle of the sun itself. A similar principle applies to God. No one has ever actually experienced the essence of God. But they have experienced his energies which brings them closer to God. Now continuing that train of thought when you’re sitting in a cave like Plato’s parable for a long time and your eyes are just exposed to the light of the sun at first it is blinding. However after a while your eyes start to accustom to the light and your experience of the sun’s rays change.
• When we look at the stories of the Old Testament what we see from a theological perspective is the experience of the Ancient Israelites with God. And what we see is an understanding that reflects a particular context, as well as development and evolution in many different areas ranging from ethics, morality, justice, etc. Its not God who’s changed. God’s essence is immutable. It is the Israelites that have changed in their development. As a result their experience of God’s divine energies is different from how they started out. When it comes to sacrifice for example, the Israelites come out of a context where sacrifice was the norm across the board. So it is present in Books like Leviticus. But then when we start to get to the Prophetic literature you have prophets like Hosea stating “I demand loving kindness and not your sacrifices”(Hosea 6:6). In Isaiah Yahweh speaking through the prophet speaks of how the sacrifices and solemn assembly are rituals that his “soul hates” because the people are doing it while shedding blood and instead demands justice for the poor, widow and orphan and oppressed(Isaiah 1:15-17). When it comes to wartime practices episodes such as Numbers 31 as well as Deuteronomy 20:10 speak of the practice of conquering a city and taking prisoners of war as wartime captives, which was the norm in warfare in most human civilizations in Ancient times. When we get to the Book of Kings we start to see a humanitarian ethic for prisoners of war in 2 Kings 6. By the time we get to 2 Chronicles 28:8-15 you have the Prophet Oded, in the name of God, demanding the release of 200,000 women and children that were war captives. As the Ancient Israelites grow in their understanding of ethics, justice and humanitarianism their experience with the Divine energies of God changes. And they growing in their understanding of God from a theological and moral perspective.

So these are some of the reasons above why I think the Classical Christian approach to the Old Testament makes logical and moral sense from a theological perspective.

So I made this post talking about how I finally got homa, but it caused me to lose a lot of CR compared to when I was using fjords. I hadn’t changed any of my artifacts at this time.
The most common suggestion on that post was to switch to an EM sands, and how it would make a huge difference in damage. I decided to test this out.
First, I updated my base build a little by swapping the flower and feather just to get 100em and a little more CR. Thanks a lot u/destinyherowolf for the suggestion! I’ll post the enka image of this base build in the comment since I want to use multiple images, but I basically ended up with – 38,826 max hp (with hydro resonance) – 1,418 attack (with homa buff) – 100 EM – 43.5% crit rate (79.5% with hunter set bonus) – 278.9% crit damage
I decided to use the best EM sands I had available, which wasn’t the best possible tbh. My HP sands is by far the best artifact I have at 49cv, while the em sands just has 12% crit rate. Again, an image of both artifacts is in the comments. With this, the build now has – 31,579 max hp (with hydro resonance) – 1,398 attack (with homa buff) – 270 EM – 49.3% crit rate (85.3% with hunter set bonus) – 243.2% crit damage
I then went to Viviane, the local legend in Fontaine to test damage. I took my usual hutao team of Yelan, Furina and Jean to test but to make sure I’m not affected by buffs which might alter results, I only used hutao’s skill at full health and then did charge attacks without using any other character’s skill or burst. I chose Viviane so that I could trigger vaporise, which is where the EM should make a difference.
The HP sands build was doing 44,200 damage while the EM build did 42,943. Was the drop in crit damage and hp significant enough to counteract any boost I got from the extra EM?

(Open to residents of Canada, excluding Quebec)
Hey, I think you’d like how simple everyday banking can be with Simplii Financial™. Use my link and you can earn when you open and use an eligible account with Simplii™. Earn $50 for a No Fee Chequing account, a High Interest Savings account, or a Personal Line of Credit.
My Simplii Financial refer-a-friend referral code for the accounts listed above is: https://mbsy.co/6mNQDc
For a No Fee Chequing Account or High Interest Savings Account you make a deposit of at least $100 within six months of opening the account, while also maintaining a minimum account balance of $100 for at least 30 days.
Open a No Fee Chequing Account by October 31, 2024 and add an eligible direct deposit of at least $100 a month for 3 straight months and you’ll earn an additional $500!
Looking for a mortgage? Did you know that Simplii Financial™ offers mortgages with incredibly low competitive rates? Use my unique code when applying for your mortgage and you could earn $100!
My code for mortgages is: 0009326391
Thanks for considering my referral!